Acceptability of cannabidiol as a treatment for people at clinical high risk for psychosis
Oliver, D.; Chesney, E.; Wallman, P.; Estrade, A.; Azis, M.; Provenzani, U.; Damiani, S.; Melillo, A.; Hunt, O.; Agarwala, S.; Minichino, A.; Uhlhaas, P. J.; McGuire, P.; Fusar-Poli, P.
Show abstract
BackgroundAt present, there are no approved pharmacological treatments for people at clinical high risk for psychosis (CHR-P). We sought to assess the acceptability of cannabidiol (CBD): a promising candidate treatment for this population. MethodsCHR-P individuals completed a survey which assessed their views on the acceptability of CBD, its expected effectiveness and side effects, and on formulation preferences. ResultsThe sample comprised 55 CHR-P individuals (24.3 years and 69% female). Most (91%) were familiar with CBD, and had previously used cannabis (64%), and around half (42%) had tried over-the-counter CBD. 75% were willing to take CBD as an intervention for mental health problems. Most participants anticipated fewer side effects with CBD than with existing medications, and preferred tablet or capsule formulations over liquids. DiscussionCBD is perceived as a highly acceptable treatment among CHR-P individuals.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Psychedelic mushrooms in the USA: Knowledge, patterns of use and association with health outcomes 95%
- Patients with affective disorders profit most from telemedical treatment: Evidence from a naturalistic patient cohort during the COVID-19 pandemic 93%
- Applications of Large Language Models in Psychiatry: A Systematic Review 92%
Similar papers in this journal
- A large Australian longitudinal cohort registry demonstrates sustained safety and efficacy of oral medicinal cannabis for at least two years 95%
- Social media discourse and internet search queries on cannabis as a medicine: A systematic review 94%
- Trace amine-associated receptor gene polymorphism increases drug craving 94%
Similar papers in this journal
- Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of First Episode Psychosis patients and controls 97%
- A Systematic Review on Psychological and Biological Mediators Between Adversity and Psychosis: Potential Targets for Treatment 93%
- Associations of cannabis use, tobacco use and incident anxiety, mood, and psychotic disorders: a systematic review and meta-analysis 93%
Similar papers in this journal
- Association of cannabis use-related predictor variables and self-reported psychotic disorders: US adults, 2001-2002 and 2012-2013 95%
- Psychiatric comorbidities in substance use disorders: Sex-based differences in a national real-world clinic sample 94%
- Trends in Prevalence of Cannabis Use Disorders among U.S. Veterans with and without Psychiatric Disorders Between 2005 and 2019 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.